Board of Directors
Corey Goodman, Ph.D.
Corey Goodman is a scientist, educator, and entrepreneur. He spent 25 years as Professor of Biology at Stanford University and Evan Rauch Chair of Neurobiology at U.C. Berkeley (Dept. of Molecular and Cell Biology), where he was a Howard Hughes Medical Institute Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute. He is currently Adjunct Professor of Neuroscience in the Wills Neuroscience Institute at U.C. Berkeley. Dr. Goodman is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, and recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Dawson Prize in Genetics from Trinity College Dublin. Dr. Goodman co-founded seven biotechnology companies (the first being Exelixis), and led one of them (Renovis) as President and CEO from a private to public company until its acquisition. He was recruited to be President and founder of Pfizer’s Biotherapeutics and Bioinnovation Center and a member of Pfizer’s executive leadership team.
Today Dr. Goodman is a Managing Partner of venBio Partners LLC. He is Chair of the Board of Solstice Biologics, Alexo Therapeutics, and Second Genome. He is a member of the Board of NFlection and Checkmate. He chaired Labrys Biologics until its acquisition by Teva. Amongst his many public policy roles, Dr. Goodman is Chair of the California Council on Science and Technology (advising the Governor and State Legislature), a member of the University of California Innovation Council, a member of the board of the Pacific Institute, and former Chair of the National Research Council's (NAS) Board on Life Sciences.
Ketan Patel, M.D.
Ketan Patel is a Partner with F-Prime Capital and has worked in the healthcare sector as an investor, consultant, and physician. Prior to joining F-Prime Capital in 2007, Dr. Patel advised biopharmaceutical and medical device companies on brand strategy, clinical development plans, and business development activities in the corporate consulting division of Leerink Swann & Company. Dr. Patel served as a physician at the VA Boston Healthcare System and at Weill Cornell Medical Center-New York Presbyterian Hospital and Memorial-Sloan Kettering Cancer Center where he completed his internal medicine training.
Dr. Patel focuses on investing in therapeutics and medical device companies and has served as a director or board observer of Aclaris Therapeutics, Acorn Cardiovascular, Amphora Medical, Bioconnect Systems, Eywa Pharma, Ivenix, Laurus Labs, Medwell Ventures, Menlo Therapeutics, NextWave Pharmaceuticals, Vicept Therapeutics, and Xcyton Diagnostics.
Dr. Patel is a graduate of Tufts University School of Medicine, where he received both his M.D. and MBA as part of that institution’s Healthcare Management Program and was elected to the Alpha Omega Alpha Medical Honor Society. He completed his undergraduate studies in biology and economics with highest honors at Rutgers University.
Mark de Souza, Ph.D., Co-Founder & Executive Chairman
Mark de Souza is an entrepreneur in the rare disease and dermatology space. He is a co-founder and CEO of Chromaderm (PKC-beta inhibitor for melasma), FIBRX Derm (topical decorin for epidermolysis bullosa), FIBRX Tissue Repair (systemic decorin for fibrotic diseases), and SCIDEC Therapeutics (intrathecal decorin for hydrocephalus and spinal cord injury). He is a co-founder of MyoTherix (P2X7 antagonist for Duchenne muscular dystrophy and Charcot Marie Tooth disease type 1A), GI Lipid Therapeutics (sphingadienes for familial adenomatous polyposis), and two BridgeBio companies in the rare skin disease space (S1P lyase inhibitor for Darier and Hailey-Hailey disease, topical KLK5/7 inhibitor for Netherton Syndrome). He was previously the Executive Chairman of PellePharm (Phase 3 topical hedgehog inhibitor for Gorlin Syndrome, partnered with LEO Pharma), founding CEO of Lotus Tissue Repair (intravenous collagen type VII for dystrophic epidermolysis bullosa, acquired by Shire, and now being developed by Phoenix Tissue Repair), and VP of Business Development at Dyax Corp (two FDA-approved plasma kallikrein inhibitors for hereditary angioedema, acquired by Shire). He is an advisor to the CureGM1 Foundation and on the board of the Special Needs Aquatic Program. He co-founded NFlection Therapeutics after his nephew was diagnosed with neurofibromatosis type 1.
Michael Wootton, Co-Founder and Chief Executive Officer
Michael is NFlection’s President and Chief Executive Officer, and also a Co-Founder. He has over fifteen years of strategy and operations consulting experience. He was formerly Partner and Life Sciences Sector Head at Celerant Consulting (acquired by Hitachi Consulting) where he worked with an array of life sciences companies including Bayer, Wyeth, Abbott, Roche, Genzyme, Fresenius, CDC, and others on large operational strategy programs. Michael is Managing Partner of Vie Capital Partners, an investment and advisory services firm focused on early and growth stage life sciences and healthcare companies. Michael has a bachelor’s degree in mechanical engineering from the University of Waterloo and an MBA from the Harvard Business School.